My site

Global organization to bring attention to system-wide improvements that will ensure better health worker and patient safety outcomes

IRVINE, Calif.-Friday 19 June 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Today, the Patient Safety Movement Foundation (PSMF) unveiled its early plans aligned with the World Health Organization’s (WHO) World Patient Safety Day on September 17, 2020. This year, WHO is focusing on the theme of health worker safety as a core priority in achieving patient safety. The Patient Safety Movement Foundation stands in support of WHO’s focus with its 2020 campaign theme: Health worker safety is patient safety. The slogan will be #uniteforsafecare.

“This year has been one of the most challenging and eye-opening for the issues of safety in our healthcare systems,” said Patient Safety Movement Foundation CEO Dr. Dave Mayer. “Even before the pandemic, more than 200,000 patients died each year in America from what are co ... Read more »

Long-time SES employee Thai Rubin to succeed John Purvis as Chief Legal Officer while Ferdinand Kayser, CEO of SES Video, to retire at year end after nearly 20 years at the company

LUXEMBOURG-Friday 19 June 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- SES today announced that Ferdinand Kayser, who has spent nearly 20 years at SES leading the video business and is presently the CEO of SES Video, has decided to retire at the end of 2020. The next six months will allow for a full and orderly transition of executive activities directly to Steve Collar, CEO of SES, who will assume responsibility for SES’s Video business from 1 July 2020. In addition to supporting the transition, Mr Kayser will take a leading role in deepening SES’s activities across government and institutions in Luxembourg and will continue to serve as Chairman of both the SES Astra and GovSat boards.

The company also announced that Thai Rubin, SES’s Executive Vice President of Legal S ... Read more »

Pluripotent cells grown from discard-worthy tissue by Edogawa hospital; World’s first such report

TOKYO-Friday 19 June 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- A break through feat of growing pluripotency expressing cells from osteoarthritis (OA) affected cartilage tissue of knee joints of elderly has been reported by orthopedicians and cell culture experts led by Dr Shojiro Katoh, President, Edogawa Hospital. OA affects, knee joints of millions globally and those with severe disease, undergo Total Knee Arthroplasty (TKA), in which damaged cartilage is replaced with artificial knee prosthesis. Dr Katoh, during TKA surgery, took portions of the damaged tissue, which otherwise is discarded, isolated chondrocyte cells in tissue engineering lab, and could culture them as fully reorganized healthy cartilage tissue, expressing biomarkers relevant to pluripotency.

Cartilage of the knee joint acts as a cushion between bones of the thigh and leg and absorbs ... Read more »

Civic Wallet Offers Verified Digital Identity and the Ability to Send Money to Friends Globally

SAN FRANCISCO-Friday 19 June 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Civic Technologies, a leading innovator in digital identity solutions, today announced that Civic Wallet, previously only available in private beta, is now generally available in the App Store and Google Play. Civic Wallet offers a safer way to store and transact with digital identity and currency around the world. Civic also announced that in response to the market need for proof-of-health verification, it will offer the ability to provide secure and regulation-compliant health checks for employers, called Health Key by Civic™.

“We built Civic Wallet because we wanted to be the first company to get it right for the consumer,” said Vinny Lingham, CEO and co-founder of Civic. “By design, Civic Wallet puts you back in the driver’s seat with more control over your d ... Read more »

FRANKFURT AM MAIN, Germany-Friday 19 June 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- The Management Board of the Northern Data AG (ISIN DE000A0SMU87, WKN A0SMU8, ticker NB2) today resolved with the approval of the Supervisory Board to increase the Company's issued share capital by issuing 431,225 new no-par value ordinary bearer shares. This corresponds to 3.64% of the current share capital. The shares are issued against cash contributions partially utilizing the existing authorized capital and excluding the existing shareholders' subscription rights. The shares are issued at EUR 50 per share; thus the total gross issue proceeds are EUR 21,561,250. All shares will be subscribed by strategic investor Block.One.

Block.One is the global leader in high performance blockchain software and author of the EOSIO open source software. Block.one and Northern Data intend to work together closely to build software infrastructure on EOSIO for North ... Read more »

LUGANO, Switzerland -Friday 19 June 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Energy Vault, the creator of products that combine conventional physics with advanced machine vision software to provide utility-scale storage of clean energy, today announced its selection as one of the World Economic Forum’s Technology Pioneers of 2020. Energy Vault’s gravity-based, long duration storage technology is transforming the way electricity is stored and distributed, making it possible – for the first time – for renewable energy to be dispatchable and competitive with fossil fuels all day, every day.

The World Economic Forum Technology Pioneers of 2020 are 100 of the most promising companies that are shaping industries from agriculture to healthcare, while also working on sustainability issues and much more. As governments around the world consider the possibility of pursuing a green recovery from the Covid-19 pandemic, Energy Vault’s technology is prov ... Read more »

TOKYO -Monday 15 June 2020 [ AETOS Wire ]

- The primary endpoint (antitumor effect) was achieved

- No new safety concerns were identified in the safety analysis

- This study was conducted as the final registration trial for the indication of relapsed or refractory PTCL. Solasia begins preparing for the NDA Filing

(BUSINESS WIRE)-- Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today announced the positive results from the pivotal Phase 2 study with SP-02 (a new anti-cancer drug, international generic name: darinaparsin, hereinafter “darinaparsin”) for relapsed or refractory peripheral T-cell lymphoma (hereinafter “PTCL”) in Asia.

The primary endpoint (antitumor effect) was achieved.
No new safety concerns were identified in the safety analysis.
This study was conducted as the fina ... Read more »